Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1 (5-Year IF – 2.0)
Journal Citation Indicator (JCI) (2023) – 0.4
Scopus CiteScore – 3.7 (CiteScore Tracker – 4.1)
Index Copernicus  – 171.00; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 10, October, p. 1453–1457

doi: 10.17219/acem/69855

Publication type: review

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Challenges in diagnosis and treatment of sporadic inclusion-body myositis

Agata Sebastian1,A,B,C,D,E,F, Maria Misterska-Skóra1,A,B,C,D,E,F, Maciej Sebastian2,A,B,C,D,E,F, Roksana Kręcichwost3,B,C,D, Katarzyna Haczkiewicz4,C,D

1 Department of Rheumatology and Internal Medicine, Faculty of Medicine, Wroclaw Medical University, Poland

2 Department of Minimally Invasive Surgery and Proctology, Faculty of Medicine, Wroclaw Medical University, Poland

3 Department of Ophthalmology, Faculty of Medicine, Wroclaw Medical University, Poland

4 Department of Histology and Embryology, Faculty of Medicine, Wroclaw Medical University, Poland

Abstract

Sporadic inclusion body myositis (sIBM) is a rare yet increasingly prevalent disease and the most common cause of inflammatory myopathy in people over the age of 50. The exact cause of the disorder is unknown. In sIBM 2 processes, first autoimmune and the other degenerative, parallelly occur in the muscle cells. The inflammation aspect is characterized by the cloning of T cells that appear to be driven by specific antigens to invade muscle fibers. The degeneration aspect is characterized by the appearance of holes in the muscle cell vacuoles, deposits of abnormal proteins within the cells and in filamentous inclusions. The disease has a major impact on patients’ motor functionality and their quality of life. The treatment of sIBM still remains a major challenge. Early diagnosis of sIBM (already at the histopathology stage), when one still cannot observe fully developed clinical symptoms, may stop help to the progression of the disease.

Key words

biomarker, early diagnosis, sporadic inclusion body myositis

References (40)

  1. Dalakas MC. Immunotherapy of inflammatory myopathies: Practical approach and future prospects. Curr Treat Options Neurol. 2011;13(3): 311–323.
  2. Yunis EJ, Samaha FJ. Inclusion body myositis. Lab Invest. 1971;25(3): 240−248.
  3. Hausmanowa-Petrusewicz I. Choroby nerwowo-mięśniowe. 2nd ed. Lublin, Poland: Czelej; 2013.
  4. Kobayashi Z, Fukatsu E, Itaya S, et al. Fist sign in inclusion body myositis. Neuromuscul Disord. 2017;27(4):385–386.
  5. Dalakas MC. Therapeutic advances and future prospects in immune-mediated inflammatory myopathies. Ther Adv Neurol Disord. 2008;1(3): 157–166.
  6. Bello R, Bertorini T, Ganta K, Mays W. A Case of asymptomatic inclusion body myositis. J Clin Neuromuscul Dis. 2017;18(3):132–134.
  7. Machado P, Brady S, Hanna MG. Update in inclusion body myositis. Curr Opin Rheumatol. 2013;25(6):763–771.
  8. Price MA, Barghout V, Benveniste O, et al. Mortality and causes of death in patients with sporadic inclusion body myositis: Survey study based on the clinical experience of specialists in Australia, Europe and the USA. J Neuromuscul Dis. 2016;3(1):67–75.
  9. Molberg Ø, Dobloug C. Epidemiology of sporadic inclusion body myositis. Curr Opin Rheumatol. 2016;28:657–660.
  10. Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain. 2011;134(Pt 11):3176–3184.
  11. Cortese A, Machado P, Morrow J, et al. Longitudinal observational study of sporadic inclusion body myositis: Implications for clinical trials. Neuromuscul Disord. 2013;23(5):404–412.
  12. Jørgensen AN, Aagaard P, Nielsen JL, et al. Physical function and muscle strength in sporadic inclusion body myositis. Muscle Nerve. 2017;56(6):50−58. doi: 10.1002/mus.25603
  13. Kumamoto T, Ueyama H, Tsumura H, Toyoshima I, Tsuda T. Expression of lysosome-related proteins and genes in the skeletal muscles of inclusion body myositis. Acta Neuropathol. 2004;107(1):59−65.
  14. Kumamoto T, Ueyama H, Watanabe S, Kominami E, Ando M. Muscle fiber degradation in distal myopathy with rimmed vacuoles. Acta Neuropathol. 1994;87(2):143–148.
  15. Rothwell S, Cooper RG, Lamb JA, Chinoy H. Entering a new phase of immunogenetics in the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 2013;25(6):735–741.
  16. Nakano S, Oki M, Kusaka H. The role of p62/SQSTM1 in sporadic inclusion body myositis. Neuromuscul Disord. 2017;27(4):363–369. doi: 10.1016/j.nmd. 2016.12.009
  17. Noda S, Koike H, Maeshima S, et al. Transforming growth factor-β signaling is upregulated in sporadic inclusion body myositis. Muscle Nerve. 2017;55(5):741–747. doi: 10.1002/mus.25405
  18. Gallay L, Petiot P. Sporadic inclusion-body myositis: Recent advances and the state of the art in 2016. Rev Neurol (Paris). 2016;172(10):581–586.
  19. Dalakas MC. Mechanisms of disease: Signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol. 2006;2(4):219–227.
  20. Dalakas MC. An update on inflammatory and autoimmune myopathies. Neuropathol Appl Neurobiol. 2011;37(3):226–242.
  21. Dalakas MC. Inflammatory myopathies: Management of steroid resistance. Curr Opin Neurol. 2011;24(5):457–462.
  22. Rygiel KA, Tuppen HA, Grady JP, et al. Complex mitochondrial DNA rearrangements in individual cells from patients with sporadic inclusion body myositis. Nucleic Acids Res. 2016;44(11):5313–5329.
  23. Hohlfeld R, Schulze-Koops H. Cytotoxic T cells go awry in inclusion body myositis. Brain. 2016;139(Pt 5):1312–1314.
  24. Greenberg SA. Inclusion body myositis. Continuum (Minneap Minn). 2016;22(6, Muscle and Neuromuscular Junction Disorders):1871–1888.
  25. Bhattarai S, Ghannam K, Krause S, et al. The immunoproteasomes are key to regulate myokines and MHC class I expression in idiopathic inflammatory myopathies. J Autoimmun. 2016;75:118–129.
  26. Güttsches AK, Brady S, Krause K, et al. Proteomics of rimmed vacuoles define new risk allele in inclusion body myositis. Ann Neurol. 2017;81(2):227–239.
  27. Catalán-García M, Garrabou G, Morén C, et al. Mitochondrial DNA disturbances and deregulated expression of oxidative phosphorylation and mitochondrial fusion proteins in sporadic inclusion body myositis. Clin Sci (Lond). 2016;130(19):1741–1751.
  28. Catalán-García M, Garrabou G, Morén C, et al. BACE-1, PS-1 and sAPPβ levels are increased in plasma from sporadic inclusion body myositis patients: Surrogate biomarkers among inflammatory myopathies. Mol Med. 2015;21(1):817–823. doi: 10.2119/molmed.2015.00168
  29. Larman BH, Salajegheh M, Nazareno R, et al. Cytosolic 5'-nucleotidase 1A autoimmunity in sporadic inclusion body myositis. Ann Neurol. 2013;73(3):408–418.
  30. Pluk H, van Hoeve BJ, van Dooren SH, et al. Autoantibodies to cytosolic 50-nucleotidase 1A in inclusion body myositis. Ann Neurol. 2013;73(3):397–407.
  31. Greenberg SA. Cytoplasmic 5’-nucleotidase autoantibodies in inclusion body myositis: Isotypes and diagnostic utility. Muscle Nerve. 2014;50(4):488–492.
  32. Kramp SL, Karayev D, Shen G, et al. Development and evaluation of a standardized ELISA for the determination of autoantibodies against cN-1A (Mup44, NT5C1A) in sporadic inclusion body myositis. Auto Immun Highlights. 2016;7(1):16.
  33. Lilleker JB, Rietveld A, Pye SR, et al.; all UKMYONET contributors. Cytosolic 5’-nucleotidase 1A autoantibody profile and clinical characteristics in inclusion body myositis. Ann Rheum Dis. 2017;76(5):862−868. doi: 10.1136/annrheumdis-2016-210282
  34. Mowzoon N, Sussman A, Bradley WG. Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis. J Neurol Sci. 2001;185(2):119–122.
  35. Keck AD, Walker UA. Therapy of myositis [in German]. Z Rheumatol. 2013;72(3):227–235.
  36. Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009;132(6):1536–1544.
  37. Schmidt K, Kleinschnitz K, Rakocevic G, Dalakas MC, Schmidt J. Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM. BMC Neurol. 2016;16:48.
  38. Machado P, Miller A, Herbelin L, et al. Safety and tolerability of arimoclomol in patients with sporadic inclusion body myositis: A randomized, double-blind, placebo-controlled, phase IIA proof-of-concept trial. Ann Rheum Dis. 2013;72:164.
  39. Ching JK, Weihl CC. Rapamycin-induced autophagy aggravates pathology and weakness in a mouse model of VCP-associated myopathy. Autophagy. 2013;9(5):799–800.
  40. Ahmed M, Machado PM, Miller A, et al. Targeting protein homeostasis in sporadic inclusion body myositis. Sci Transl Med. 2016;8(331):
© Wroclaw Medical University